Trials / Completed
CompletedNCT01535729
An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Erlotinib (Tarceva®) in Routine Clinical Practice in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapy Regimen With Focus on the Elderly Patient.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 465 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in elderly patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. Data of patients treated with Tarceva in routine clinical practice will be collected for 1 year.
Conditions
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2012-02-20
- Last updated
- 2015-10-29
- Results posted
- 2015-10-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01535729. Inclusion in this directory is not an endorsement.